IBDEI2UF ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,47712,0)
 ;;=C95.91^^209^2346^240
 ;;^UTILITY(U,$J,358.3,47712,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47712,1,3,0)
 ;;=3^Leukemia,Unspec,In Remission
 ;;^UTILITY(U,$J,358.3,47712,1,4,0)
 ;;=4^C95.91
 ;;^UTILITY(U,$J,358.3,47712,2)
 ;;=^5001857
 ;;^UTILITY(U,$J,358.3,47713,0)
 ;;=C95.92^^209^2346^239
 ;;^UTILITY(U,$J,358.3,47713,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47713,1,3,0)
 ;;=3^Leukemia,Unspec,In Relapse
 ;;^UTILITY(U,$J,358.3,47713,1,4,0)
 ;;=4^C95.92
 ;;^UTILITY(U,$J,358.3,47713,2)
 ;;=^5001858
 ;;^UTILITY(U,$J,358.3,47714,0)
 ;;=C96.0^^209^2346^347
 ;;^UTILITY(U,$J,358.3,47714,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47714,1,3,0)
 ;;=3^Multifocal/Multisystemic Langerhans-Cell Histiocytosis
 ;;^UTILITY(U,$J,358.3,47714,1,4,0)
 ;;=4^C96.0
 ;;^UTILITY(U,$J,358.3,47714,2)
 ;;=^5001859
 ;;^UTILITY(U,$J,358.3,47715,0)
 ;;=C96.2^^209^2346^283
 ;;^UTILITY(U,$J,358.3,47715,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47715,1,3,0)
 ;;=3^Malig Mast Cell Tumor
 ;;^UTILITY(U,$J,358.3,47715,1,4,0)
 ;;=4^C96.2
 ;;^UTILITY(U,$J,358.3,47715,2)
 ;;=^5001860
 ;;^UTILITY(U,$J,358.3,47716,0)
 ;;=C96.4^^209^2346^452
 ;;^UTILITY(U,$J,358.3,47716,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47716,1,3,0)
 ;;=3^Sarcoma of Dendritic Cells
 ;;^UTILITY(U,$J,358.3,47716,1,4,0)
 ;;=4^C96.4
 ;;^UTILITY(U,$J,358.3,47716,2)
 ;;=^5001861
 ;;^UTILITY(U,$J,358.3,47717,0)
 ;;=C96.5^^209^2346^348
 ;;^UTILITY(U,$J,358.3,47717,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47717,1,3,0)
 ;;=3^Multifocal/Unisystemic Langerhans-Cell Histiocytosis
 ;;^UTILITY(U,$J,358.3,47717,1,4,0)
 ;;=4^C96.5
 ;;^UTILITY(U,$J,358.3,47717,2)
 ;;=^5001862
 ;;^UTILITY(U,$J,358.3,47718,0)
 ;;=C96.6^^209^2346^477
 ;;^UTILITY(U,$J,358.3,47718,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47718,1,3,0)
 ;;=3^Uniforcal Langerhans-Cell Histiocytosis
 ;;^UTILITY(U,$J,358.3,47718,1,4,0)
 ;;=4^C96.6
 ;;^UTILITY(U,$J,358.3,47718,2)
 ;;=^5001863
 ;;^UTILITY(U,$J,358.3,47719,0)
 ;;=C96.A^^209^2346^214
 ;;^UTILITY(U,$J,358.3,47719,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47719,1,3,0)
 ;;=3^Histiocytic Sarcoma
 ;;^UTILITY(U,$J,358.3,47719,1,4,0)
 ;;=4^C96.A
 ;;^UTILITY(U,$J,358.3,47719,2)
 ;;=^5001865
 ;;^UTILITY(U,$J,358.3,47720,0)
 ;;=C96.Z^^209^2346^284
 ;;^UTILITY(U,$J,358.3,47720,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47720,1,3,0)
 ;;=3^Malig Neop of Lymphoid/Hematopoietic/Related Tissue NEC
 ;;^UTILITY(U,$J,358.3,47720,1,4,0)
 ;;=4^C96.Z
 ;;^UTILITY(U,$J,358.3,47720,2)
 ;;=^5001866
 ;;^UTILITY(U,$J,358.3,47721,0)
 ;;=C96.9^^209^2346^285
 ;;^UTILITY(U,$J,358.3,47721,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47721,1,3,0)
 ;;=3^Malig Neop of Lymphoid/Hematopoietic/Related Tissue,Unspec
 ;;^UTILITY(U,$J,358.3,47721,1,4,0)
 ;;=4^C96.9
 ;;^UTILITY(U,$J,358.3,47721,2)
 ;;=^5001864
 ;;^UTILITY(U,$J,358.3,47722,0)
 ;;=C43.51^^209^2347^1
 ;;^UTILITY(U,$J,358.3,47722,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47722,1,3,0)
 ;;=3^Malig Melanoma of Anal Skin
 ;;^UTILITY(U,$J,358.3,47722,1,4,0)
 ;;=4^C43.51
 ;;^UTILITY(U,$J,358.3,47722,2)
 ;;=^5001005
 ;;^UTILITY(U,$J,358.3,47723,0)
 ;;=C43.52^^209^2347^2
 ;;^UTILITY(U,$J,358.3,47723,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47723,1,3,0)
 ;;=3^Malig Melanoma of Breast Skin
 ;;^UTILITY(U,$J,358.3,47723,1,4,0)
 ;;=4^C43.52
 ;;^UTILITY(U,$J,358.3,47723,2)
 ;;=^5001006
 ;;^UTILITY(U,$J,358.3,47724,0)
 ;;=C43.30^^209^2347^4
 ;;^UTILITY(U,$J,358.3,47724,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47724,1,3,0)
 ;;=3^Malig Melanoma of Face,Unspec
 ;;^UTILITY(U,$J,358.3,47724,1,4,0)
 ;;=4^C43.30
